Described is a nutritional formula, also referred to as a nutritional formulation, for dietary management of a propionic metabolism disorder, such as propionic acidemia.

Described is a nutritional formula, also referred to as a nutritional formulation, for dietary management of a propionic metabolism disorder, such as propionic acidemia.

A pre-workout coffee creamer composition including a powdered workout supplement in the form of a non-dairy creamer which may be added to coffee or tea to deliver nutrients orally to boost energy. The non-dairy creamer includes a mixture of creatine, Beta-alanine, L-arginine, at least one flavoring agent, at least one B vitamin, Taurine, Tyrosine, electrolytes, and a sweetener. The composition may be provided in a powdered or liquid form. The non-dairy creamer may further include caffeine.

A pre-workout coffee creamer composition including a powdered workout supplement in the form of a non-dairy creamer which may be added to coffee or tea to deliver nutrients orally to boost energy. The non-dairy creamer includes a mixture of creatine, Beta-alanine, L-arginine, at least one flavoring agent, at least one B vitamin, Taurine, Tyrosine, electrolytes, and a sweetener. The composition may be provided in a powdered or liquid form. The non-dairy creamer may further include caffeine.

Provided are processes of reducing and/or eliminating risk factors associated with metabolic syndrome in a subject through the administration of a nelumbo extract. The nelumbo extract supplement is administered orally, intravenously, or subcutaneously. In one aspect, a daily dose of 10-1,000 mg of the extract supplement is administered to the subject for a period of 6 weeks to 6 months.

Provided are processes of reducing and/or eliminating risk factors associated with metabolic syndrome in a subject through the administration of a nelumbo extract. The nelumbo extract supplement is administered orally, intravenously, or subcutaneously. In one aspect, a daily dose of 10-1,000 mg of the extract supplement is administered to the subject for a period of 6 weeks to 6 months.

The present invention describes a method for providing creatine to an animal, which includes receiving a creatine ester by the animal. The creatine ester is suitable for being modified by the animal to form creatine.

The present invention describes a method for providing creatine to an animal, which includes receiving a creatine ester by the animal. The creatine ester is suitable for being modified by the animal to form creatine.

The present invention is directed to an oral supplement including creatine hydrochloride, which has an aqueous solubility that is at least 15 times greater than creatine monohydrate, where the oral supplement drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.

The present invention is directed to an oral supplement including creatine hydrochloride, which has an aqueous solubility that is at least 15 times greater than creatine monohydrate, where the oral supplement drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.